Furthermore, our multimodal framework—integrating MRI-based 2.5D DL, as well as radiomics and clinical features—may noninvasively predict HCC MVI/Ki-67 dual biomarkers preoperatively, thus overcoming limitations of invasive biopsies or postoperative pathological examinations. This evidence concerns the gene MKI67 and hepatocellular carcinoma.